PRX-08066 Maleic acid
CAS No. 866206-55-5
PRX-08066 Maleic acid( PRX-08066 Maleate )
Catalog No. M19194 CAS No. 866206-55-5
PRX-08066 Maleic acid is a selective 5-HT2B receptor antagonist with IC50 of 3.4 nM, prevents the severity of pulmonary arterial hypertension in the MCT rat model. Phase 2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 162 | In Stock |
|
10MG | 221 | In Stock |
|
25MG | 398 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePRX-08066 Maleic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionPRX-08066 Maleic acid is a selective 5-HT2B receptor antagonist with IC50 of 3.4 nM, prevents the severity of pulmonary arterial hypertension in the MCT rat model. Phase 2.
-
DescriptionPRX-08066 Maleate is a novel potent and selective 5-HT2B receptor antagonist.
-
In Vitro——
-
In Vivo——
-
SynonymsPRX-08066 Maleate
-
PathwayOthers
-
TargetOther Targets
-
Recptor5-HT2B
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number866206-55-5
-
Formula Weight517.96
-
Molecular FormulaC19H17ClFN5S·C4H4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1CN(CCC1NC2=C3C=C(SC3=NC=N2)Cl)CC4=CC(=C(C=C4)F)C#N.C(=C\C(=O)O)\C(=O)O
-
Chemical Name5-[[4-[(6-Chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]-2-fluorobenzonitrile maleate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
3-Methoxymirificin
3'-Methoxymirificin is a natural product for research related to life sciences.
-
Clemaphenol A
Clemaphenol A is a natural product from Cynanchum auriculatum.
-
NADH disodium salt h...
NADH is the reduced form of nicotinamide adenine dinucleotide (NAD) that can donate electrons as part of a reducing reaction. In that process NADH becomes oxidized to produce NAD+. A variety of enzymes use NADH plus H+ to reduce substrates generating NAD+ as well as the reduced product.